Literature DB >> 20590606

Oral sildenafil increases skin hyperaemia induced by iontophoresis of sodium nitroprusside in healthy volunteers.

S Blaise1, M Hellmann, M Roustit, S Isnard, J L Cracowski.   

Abstract

BACKGROUND AND
PURPOSE: Sildenafil, a specific inhibitor of phosphodiesterase 5A (PDE5A), is currently tested as a treatment for severe Raynaud's phenomenon. Here, we tested whether sildenafil, alone or combined with local sodium nitroprusside (SNP) delivered through skin iontophoresis, increased forearm cutaneous blood conductance in healthy volunteers, and to assess how well this combination was tolerated. EXPERIMENTAL APPROACH: Ten healthy volunteers were enrolled. Variations in cutaneous vascular conductance (CVC) following oral administration of 50 or 100 mg of sildenafil with or without SNP iontophoresis were expressed as a percentage of maximal CVC, and were monitored using laser Doppler imaging. SNP iontophoresis was performed on the ventral surface of the forearm, 1 h after application of lidocaine/prilocaine cream. KEY
RESULTS: Sildenafil at 100 mg, but not 50 mg, increased overall responses (area under the curve) (44%) and peak responses (29%) to SNP iontophoresis. Sildenafil at 100 mg, but not 50 mg, increased baseline CVC (75%). Incidence of headache was not changed when SNP iontophoresis was combined with sildenafil. One episode of symptomatic arterial hypotension occurred in a volunteer given 50 mg sildenafil, 30 min after the beginning of SNP iontophoresis. CONCLUSIONS AND IMPLICATIONS: Oral sildenafil at 100 mg potentiated local skin hyperaemia induced by SNP iontophoresis, with no increased incidence of headaches. The combination of oral specific PDE5A inhibitor and nitrates administered through skin iontophoresis deserves further investigation in diseases such as severe Raynaud's phenomenon, with particular attention to the incidence of arterial hypotension.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590606      PMCID: PMC2936022          DOI: 10.1111/j.1476-5381.2010.00778.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Severe digital ischaemia treated with phosphodiesterase inhibitors.

Authors:  C R Kumana; G T Y Cheung; C S Lau
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

2.  Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.

Authors:  J Gore; R Silver
Journal:  Ann Rheum Dis       Date:  2005-09       Impact factor: 19.103

3.  Possible therapeutic use of vasodilator iontophoresis.

Authors:  Andrea K Murray; Ariane L Herrick; Rachel E Gorodkin; Tonia L Moore; Terence A King
Journal:  Microvasc Res       Date:  2005-01       Impact factor: 3.514

Review 4.  ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association.

Authors:  M D Cheitlin; A M Hutter; R G Brindis; P Ganz; S Kaul; R O Russell; R M Zusman
Journal:  J Am Coll Cardiol       Date:  1999-01       Impact factor: 24.094

5.  Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.

Authors:  Roland Fries; Kaveh Shariat; Hubertus von Wilmowsky; Michael Böhm
Journal:  Circulation       Date:  2005-11-08       Impact factor: 29.690

6.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

7.  Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina.

Authors:  D J Webb; G J Muirhead; M Wulff; J A Sutton; R Levi; W W Dinsmore
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

8.  Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease.

Authors:  A G Franks
Journal:  Lancet       Date:  1982-01-09       Impact factor: 79.321

9.  Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric, prospective, double-blind, placebo-controlled, randomized cross-over study.

Authors:  J W Park; C Mrowietz; N Chung; F Jung
Journal:  Clin Hemorheol Microcirc       Date:  2004       Impact factor: 2.375

10.  Sodium nitroprusside iontophoresis on the finger pad does not consistently increase skin blood flow in healthy controls and patients with systemic sclerosis.

Authors:  M Roustit; S Blaise; J L Cracowski
Journal:  Microvasc Res       Date:  2009-03-06       Impact factor: 3.514

View more
  6 in total

1.  Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials.

Authors:  Heather Gladue; Paul Maranian; Harold E Paulus; Dinesh Khanna
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-04       Impact factor: 4.794

2.  Cathodal iontophoresis of treprostinil and iloprost induces a sustained increase in cutaneous flux in rats.

Authors:  S Blaise; M Roustit; C Millet; C Ribuot; J Boutonnat; J L Cracowski
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Potentiation of the NO-cGMP pathway and blood flow responses during dynamic exercise in healthy humans.

Authors:  Jacqueline K Limberg; Katherine R Malterer; J Mikhail Kellawan; William G Schrage; Brad W Wilkins; Wayne T Nicholson; John H Eisenach; Michael J Joyner; Timothy B Curry
Journal:  Eur J Appl Physiol       Date:  2016-12-24       Impact factor: 3.078

4.  Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud's phenomenon.

Authors:  M Roustit; M Hellmann; C Cracowski; S Blaise; J L Cracowski
Journal:  Clin Pharmacol Ther       Date:  2012-03-28       Impact factor: 6.875

5.  Regional myocardial function abnormalities are associated with macro- and microcirculation dysfunction in the metabolic syndrome: the RESOLVE study.

Authors:  Philippe Obert; Guillaume Walther; Frédéric Dutheil; Bruno Lesourd; Robert Chapier; Daniel Courteix; Agnes Vinet
Journal:  Heart Vessels       Date:  2018-01-19       Impact factor: 2.037

6.  Iontophoresis of endothelin receptor antagonists in rats and men.

Authors:  Matthieu Roustit; Sophie Blaise; Claire Arnaud; Marcin Hellmann; Claire Millet; Diane Godin-Ribuot; Boris Dufournet; Jean Boutonnat; Christophe Ribuot; Jean-Luc Cracowski
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.